Infectious Disease ·
International guidelines set standards for personalized phage therapy
An international consensus group has issued more than 60 recommendations for selecting, testing, manufacturing, administering and monitoring personalized bacteriophage therapy. The guidance addresses an experimental approach to difficult bacterial infections; controlled trials have not yet established its effectiveness, and the recommendations do not support routine use.
- Consensus guidance includes more than 60 recommendations.
- Phage matching and multidisciplinary decisions are emphasized.
- A 100-patient case series reported improvement in 77%.
- Guidelines do not recommend routine use; efficacy remains uncertain.
An international group led by the German Society for Infectious Diseases developed clinical guidance for personalized bacteriophage therapy through a structured consensus process. The effort involved 20 professional organizations, 18 experts, including regulatory representatives, and two patient advocacy organizations. The recommendations cover phage selection and susceptibility testing, manufacturing and quality control, administration, monitoring, laboratory infrastructure and treatment documentation.
The guidance describes phage therapy as a possible option when established treatments have failed, are unavailable or cannot be used safely. Because phages may act against specific bacterial strains, laboratories should test whether candidate phages can target the organisms causing an individual patient’s infection. The group calls for decisions involving treating physicians, clinical microbiologists and phage specialists, alongside systematic documentation and registry reporting.
The article cites a Belgian case series of 100 treated patients: 77% improved clinically and targeted bacteria were no longer detected in 61% of cases. These observational findings cannot establish that phages caused the outcomes. The guidelines do not recommend routine use; controlled clinical trials have not yet provided sufficient evidence of efficacy. The recommendations are valid through June 29, 2030, with annual review planned.
In practice
For patients with difficult bacterial infections when established treatments have failed, are unavailable or cannot be used safely, the guidance provides a framework for considering personalized phage therapy. It calls for laboratory matching of phages to the infecting strain and decisions involving treating clinicians, microbiologists and phage experts, with quality controls and treatment documentation. This is not a recommendation for routine use: controlled trials have not established efficacy, and the cited 100-patient case series cannot determine whether phages caused the reported improvements.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Nature Medicine (via ScienceDaily): Scientists turn viruses into weapons against deadly superbugs ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.